Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

TakeAim Leukemia FLT3 Clinical Outcomes EHA 2024 Poster

Monday, June 17, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Curis Inc. is preparing to present a poster on the clinical outcomes of its TakeAim Leukemia study at EHA 2024. The company continues to focus on its pipeline, which includes various therapies for hematological malignancies. Details regarding the specific outcomes and implications of the study will be shared during the event.
Price reaction · baseline $162.6 (2024-06-14 close) · hit pre-market · clean, no other CRIS news in the window
day 0 close
+1.1%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What is the TakeAim Leukemia study?

The TakeAim Leukemia study focuses on evaluating therapies for leukemia, particularly targeting FLT3 mutations.

When will the EHA 2024 presentation occur?

The presentation of the TakeAim Leukemia clinical outcomes will take place during the EHA 2024 event.

What company is behind the TakeAim studies?

Curis Inc. is the company conducting the TakeAim studies, including those for leukemia.

What are the key therapies in Curis' pipeline?

Curis' pipeline includes therapies like Emavusertib, Fimepinostat, and CA-170.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Curis TakeAim Leukemia FLT3 EHA 2024
Last updated: Jun 17, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →